產(chǎn)品詳情

  • 產(chǎn)品名稱：Ticagrelor

  • 產(chǎn)品型號(hào)：
  • 產(chǎn)品廠商：TargetMol
  • 產(chǎn)品文檔：
你添加了1件商品 查看購(gòu)物車
簡(jiǎn)單介紹：
Ticagrelor
詳情介紹：
Purpose Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
Characteristics Tradename: AZD6140
Source of Compound: synthetic
Target: P2 Receptor inhibitor
Receptor: P2Y Receptor
Status: USP
Purification All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
Purity 99?%
Formula C23H28F2N6O4S
Solubility Water: 10 μg/mL
Molecular Weight 522.57 g/mol
CAS-No 274693-27-5
Application Notes Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Format Solid
Storage -20 °C
Storage Comment For the majority of compounds, they could be dissolved in DMSO or other organic solvent.
Their stock solution can be stored at -20°C for up to 3 months and aliquoted for sampling convenience.
Several freeze/thaw cycles should not damage the activity of our small molecule products.
However, in many instances the aqueous solutions of some compounds need to be made fresh and cannot be stored. For these compounds, their solution should be prepared just before use and stored no longer than 24 hours.
Expiry Date 24 months